Press coverage about Insulet (NASDAQ:PODD) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Insulet earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave news stories about the medical instruments supplier an impact score of 46.1408785507793 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- Insulet (PODD) Rating Lowered to Strong Sell at Zacks Investment Research (americanbankingnews.com)
- Insulet (PODD) Scheduled to Post Earnings on Thursday (americanbankingnews.com)
- Global Insulin delivery system Market Competitive landscape: Insulet Corporation, Animas Corporation (marketwatch.com)
- Brokerages Anticipate Insulet Co. (PODD) Will Announce Quarterly Sales of $121.60 Million (americanbankingnews.com)
- Zacks: Analysts Expect Insulet Co. (PODD) Will Announce Earnings of -$0.19 Per Share (americanbankingnews.com)
PODD has been the topic of several research reports. Barclays reiterated an “overweight” rating and set a $90.00 price objective (up previously from $85.00) on shares of Insulet in a report on Thursday, February 22nd. BidaskClub upgraded shares of Insulet from a “buy” rating to a “strong-buy” rating in a report on Friday, March 23rd. Berenberg Bank initiated coverage on shares of Insulet in a report on Friday, April 20th. They issued a “buy” rating and a $100.00 target price on the stock. Guggenheim initiated coverage on shares of Insulet in a report on Tuesday, April 3rd. They issued a “buy” rating and a $105.00 target price on the stock. Finally, Zacks Investment Research lowered shares of Insulet from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $76.32.
Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.04). Insulet had a negative return on equity of 29.73% and a negative net margin of 5.79%. The firm had revenue of $130.50 million during the quarter, compared to the consensus estimate of $125.16 million. During the same period in the previous year, the company posted ($0.16) earnings per share. The company’s revenue for the quarter was up 26.0% on a year-over-year basis. equities analysts expect that Insulet will post -0.29 EPS for the current year.
In other Insulet news, Director David A. Lemoine sold 641 shares of the company’s stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $76.81, for a total value of $49,235.21. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Bradley A. Thomas sold 3,500 shares of the company’s stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $85.00, for a total transaction of $297,500.00. The disclosure for this sale can be found here. Insiders sold a total of 28,800 shares of company stock valued at $2,412,739 over the last ninety days. 3.60% of the stock is currently owned by insiders.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.